Logo.png
Fuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsight
31 juil. 2024 13h00 HE | DelveInsight Business Research LLP
New York, USA, July 31, 2024 (GLOBE NEWSWIRE) -- Fuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsight  The market for Fuchs...
34945.jpg
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
29 janv. 2019 08h30 HE | ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
34945.jpg
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
23 avr. 2018 07h00 HE | ProQR Therapeutics N.V.
Key Updates Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled.The trial is on track to announce interim six-month data on...